Oturkibart

奥托奇拜单抗

Report date: 2026/05/08 10:00:28

Base Information

Drug NameOturkibart
Drug Alias Name重组人源化抗IL-4Rα单克隆抗体注射液QX-005NHDM3016HDM-3016
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsChronic UrticariaPrurigoDermatitis, Atopic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQyuns Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuadong Medicine Co LtdQyuns Therapeutics Co LtdHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic UrticariaPrurigoDermatitis, Atopic +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A